Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
James C Hamilton sold 32,729 shares of ARWR on 6 January at $20.11 per share, worth a total of $658K. They now own 283,093 ARWR shares, or a 11% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.